The global flow diverters market size was estimated to be USD 0.304 billion in 2023 and is expected to reach at USD 1.21 billion by 2034 with a CAGR of 13.37% during the forecast period 2024-2034. An increase in the frequency of brain aneurysms and the risk factors linked to them, rising preference for minimally invasive procedures, growing public knowledge of government programs and treatments aimed at reducing the incidence of intracranial aneurysm, surge in geriatric population, increasing investment in R&D for launching technologically advanced minimally invasive surgical instruments, rising launch of technologically advanced products, growing healthcare expenditure, and surge in partnerships & collaborations among key market players are some of the key factors boosting the market growth.
Surge in partnerships & collaborations among key market players is predicted to boost the market growth during the forecast period. The primary purpose of flow diverters, which are inserted into the parent artery to redirect blood flow, is to cure incurable cerebral aneurysms. For instance, in August 2022, The distributorship of eleven neurovascular therapy devices has been completed under the terms of an amended exclusive Japanese distribution agreement between Wallaby Medical Holding, Inc. and Japan Lifeline Co., Ltd. Commencing in August 2022, the deal has a ten-year duration. Included in the arrangement is the Avenir Coil System, which Japan Lifeline introduced in the previous year.
By diameter size, >5 mm flow diverters was the highest revenue-grossing segment in the global flow diverters market in 2023. More than 10 mm in diameter cerebral aneurysms can be treated with the >5 mm. Consequently, the devices are usually inserted into big blood arteries with a high occlusion rate using these large diameter diverters. This is because most ruptured aneurysms are larger, measuring more than 10.0 mm in diameter. This is because of its broad-spectrum utility in treating big and wide-neck cerebral aneurysms. Therefore, devices larger than 5 mm are the best to implant in big arteries in order to increase the rate of stable aneurysm occlusion. Because of these benefits and many approvals, this market sector is predicted to dominate in the upcoming years. Additionally, 3-4 mm flow diverters is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of product approvals, growing demand for minimally invasive procedures, and increasing collaborations within market players. For instance, in February 2022, Vocera Communications is a supplier of digital care coordination. Stryker Corporation bought Vocera Communications to further its innovations, fulfill its digital objectives, and make patient care safer.
By end-user, hospital & clinics was the highest revenue-grossing segment in the global flow diverters market in 2023 owing to the growing prevalence of neurological disorders, surge in number of patients with aneurysm admitting to hospitals, and rising number of surgical procedures. For instance, in February 2022, The first FRED X flow diverter device clinical case in the United States was disclosed by MicroVention, Inc., a Terumo Corporation subsidiary, at Thomas Jefferson University Hospital in Philadelphia. With MicroVention X Technology, a patented nano-polymer surface modification, the FRED X Flow Diverter's material thrombogenicity-or propensity for clot formation-is reduced. Additionally, ambulatory surgical center is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of cutting-edge technologies, rising healthcare expenditures, and growing preference by patients for outsourcing healthcare services.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of intracranial aneurysm, growing demand for minimally invasive neurological procedures, surge in supportive government initiatives, increasing favorable reimbursements, rising partnerships within market players. For instance, in June 2022, The collaboration between Carmeda and Stryker will enhance the management of brain aneurysms by combining Carmeda's active heparin coating with Stryker's well-proven flow diverter technology. CBAS Heparin Surface is another name for CARMEDA BioActive Surface, the active heparin coating. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to an enormous patient population with neurovascular diseases, increasing healthcare expenditures, growing technological advancements, and rising introduction of novel products. For instance, in June 2022, The fourth-generation flow diverter, Pipeline Vantage with Shield Technology, certified by CE, is now available for endovascular treatment of brain aneurysms by India Medtronic Private Limited. A novel flow diverter with improved delivery system and implant design characteristics is Pipeline Vantage with Shield Technology.
Surge in partnerships & collaborations among key market players is predicted to boost the market growth during the forecast period. The primary purpose of flow diverters, which are inserted into the parent artery to redirect blood flow, is to cure incurable cerebral aneurysms. For instance, in August 2022, The distributorship of eleven neurovascular therapy devices has been completed under the terms of an amended exclusive Japanese distribution agreement between Wallaby Medical Holding, Inc. and Japan Lifeline Co., Ltd. Commencing in August 2022, the deal has a ten-year duration. Included in the arrangement is the Avenir Coil System, which Japan Lifeline introduced in the previous year.
By diameter size, >5 mm flow diverters was the highest revenue-grossing segment in the global flow diverters market in 2023. More than 10 mm in diameter cerebral aneurysms can be treated with the >5 mm. Consequently, the devices are usually inserted into big blood arteries with a high occlusion rate using these large diameter diverters. This is because most ruptured aneurysms are larger, measuring more than 10.0 mm in diameter. This is because of its broad-spectrum utility in treating big and wide-neck cerebral aneurysms. Therefore, devices larger than 5 mm are the best to implant in big arteries in order to increase the rate of stable aneurysm occlusion. Because of these benefits and many approvals, this market sector is predicted to dominate in the upcoming years. Additionally, 3-4 mm flow diverters is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of product approvals, growing demand for minimally invasive procedures, and increasing collaborations within market players. For instance, in February 2022, Vocera Communications is a supplier of digital care coordination. Stryker Corporation bought Vocera Communications to further its innovations, fulfill its digital objectives, and make patient care safer.
By end-user, hospital & clinics was the highest revenue-grossing segment in the global flow diverters market in 2023 owing to the growing prevalence of neurological disorders, surge in number of patients with aneurysm admitting to hospitals, and rising number of surgical procedures. For instance, in February 2022, The first FRED X flow diverter device clinical case in the United States was disclosed by MicroVention, Inc., a Terumo Corporation subsidiary, at Thomas Jefferson University Hospital in Philadelphia. With MicroVention X Technology, a patented nano-polymer surface modification, the FRED X Flow Diverter's material thrombogenicity-or propensity for clot formation-is reduced. Additionally, ambulatory surgical center is predicted to grow at fastest CAGR during the forecast period owing to the increasing adoption of cutting-edge technologies, rising healthcare expenditures, and growing preference by patients for outsourcing healthcare services.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of intracranial aneurysm, growing demand for minimally invasive neurological procedures, surge in supportive government initiatives, increasing favorable reimbursements, rising partnerships within market players. For instance, in June 2022, The collaboration between Carmeda and Stryker will enhance the management of brain aneurysms by combining Carmeda's active heparin coating with Stryker's well-proven flow diverter technology. CBAS Heparin Surface is another name for CARMEDA BioActive Surface, the active heparin coating. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to an enormous patient population with neurovascular diseases, increasing healthcare expenditures, growing technological advancements, and rising introduction of novel products. For instance, in June 2022, The fourth-generation flow diverter, Pipeline Vantage with Shield Technology, certified by CE, is now available for endovascular treatment of brain aneurysms by India Medtronic Private Limited. A novel flow diverter with improved delivery system and implant design characteristics is Pipeline Vantage with Shield Technology.
Segmentation: Flow Diverters Market Report 2023 - 2034
Flow Diverters Market Analysis & Forecast by Diameter Size 2023 - 2034 (Revenue USD Bn)
- >5 mm Flow Diverters
- 4-5 mm Flow Diverters
- 3-4 mm Flow Diverters
- 2-3 mm Flow Diverters
Flow Diverters Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Hospital & Clinics
- Ambulatory Surgical Center
Flow Diverters Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Flow Diverters Market: Diameter Size Estimates & Trend Analysis
8. Flow Diverters Market: End-user Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Flow Diverters Market
11. Europe Global Flow Diverters Market
12. Asia Pacific Global Flow Diverters Market
13. Latin America Global Flow Diverters Market
14. MEA Global Flow Diverters Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Acandis GmbH
- Medtronic plc
- Phenox GmbH
- Cerus Endovascular Inc.
- Stryker Corporation
- InspireMD Inc.
- MicroPort Scientific Corporation
- Balt
- MicroVention Inc. (Terumo Corporation)
- CERENOVUS (Johnson & Johnson Services Inc.)
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 0.3 Billion |
| Forecasted Market Value ( USD | $ 1.21 Billion |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
